Diferencia entre revisiones de «Proyecto Hipertensión Pulmonar/en»

De Tecnología Médica para el Desarrollo Sostenible
Saltar a: navegación, buscar
(Página creada con «<div style="border:none; margin-left: 2em; margin-right: 5em; text-align: justify; padding-left:5px; text-indent: 3%; color:#000"> This new project, which focuses on pulmo...»)
Línea 13: Línea 13:
 
</div>
 
</div>
  
<div class="mw-translate-fuzzy">
+
=== <big>Summary</big> ===
<div style="border:none; margin-left: 2em;  margin-right: 5em; text-align: justify; padding-left:5px; text-indent: 3%; color:#000">
+
<big>In search of new imaging biomarkers for pulmonary hypertension.</big>
This new project, which focuses on pulmonary hypertension, is aimed at analysing its specific radiological manifestations, especially in computed tomography, in order to identify new biomarkers based on images. These indicators will be obtained from the phenotyping functions available in the IPC or versions of them adapted to the singularities of pulmonary hypertension. The new biomarkers are expected to aid in the diagnosis and prognosis of this pathology.
 
</div>
 
</div>
 
  
 
<div style="border:none; margin-left: 2em;  margin-right: 5em; text-align: justify; padding-left:5px; text-indent: 3%; color:#000">
 
<div style="border:none; margin-left: 2em;  margin-right: 5em; text-align: justify; padding-left:5px; text-indent: 3%; color:#000">

Revisión del 15:38 7 jun 2018

Otros idiomas:
English • ‎español

Hipertensión Pulmonar

Pulmonary hypertension is a pathology characterized by a significant increase in blood pressure in the pulmonary arteries. Although its incidence in the population is low, its prognosis is usually poor, especially at the stages in which it is diagnosed. In addition, it is not infrequent for young people to be affected, with a higher incidence in women, and this has aroused the interest of the scientific community in the development of strategies to speed up diagnosis and improve predictability in the evolution of patients.

The starting point of this project is the work carried out at the Harvard Medical School in Boston –partner institution of the MACbioIDi project– by the researchers Raúl San José Estepar, Ph.D., and Jorge Onieva Onieva, M.Sc. in the context of Chronic Obstructive Pulmonary Disease. Their team has developed and integrated in 3D Slicer the Chest Imaging Platform (http://chestimagingplatform.org) which provides a whole set of tools for computed tomography image analysis, including modules for lung segmentation and vessel and airway reconstruction. It also helps to extract characteristics of the pulmonary vasculature (phenotyping).

Summary

In search of new imaging biomarkers for pulmonary hypertension.

La hipertensión pulmonar es una patología caracterizada por un aumento significativo en la presión sanguínea en las arterias pulmonares. Aunque su incidencia en la población es baja, su pronóstico suele ser malo, especialmente en los estadios en los que es diagnosticada. Esto, unido a que no es infrecuente que afecte a personas jóvenes (con mayor incidencia en mujeres), ha despertado el interés de la comunidad científica en el desarrollo de estrategias que agilicen el diagnóstico y mejoren la previsión en la evolución de los pacientes.

El punto de partida de este proyecto es el trabajo realizado en la Harvard Medical School de Boston –entidad socia del proyecto MACbioIDi– por los investigadores Dr. Raúl San José Estepar y M.C. Jorge Onieva Onieva, en el contexto de la Enfermedad Pulmonar Obstructiva Crónica. Su equipo ha desarrollado e integrado en 3D Slicer la pltaforma CIP (Chest Imaging Platform - http://chestimagingplatform.org) que proporciona numerosas herramientas para el análisis de imágenes tomográficas, incluyendo módulos para la segmentación de pulmones y la reconstrucción de vasos y vías aéreas. Facilita igualmente la extracción de características (fenotipado) de la vasculatura pulmonar.

This new project, which focuses on pulmonary hypertension, is aimed at analysing its specific radiological manifestations, especially in computed tomography, in order to identify new biomarkers based on images. These indicators will be obtained from the phenotyping functions available in the IPC or versions of them adapted to the singularities of pulmonary hypertension. The new biomarkers are expected to aid in the diagnosis and prognosis of this pathology.